6 April 2024 in npj Vaccines
Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate vaccines aimed at inducing broadly neutralizing antibodies. While state-of-the-art SOSIP or single-chain Env designs can be expressed as native-like trimers, undesired monomers, dimers and malformed trimers that elicit non-neutralizing antibodies are also formed, implying that these designs could benefit from further modifications for gene-based vaccination approaches. Here, we describe the triple tandem trimer (TTT) design, in which three Env protomers are genetically linked in a single open reading frame and express as native-like trimers. Viral vectored Env TTT induced similar neutralization titers but with a higher proportion of trimer-specific responses. The TTT design was also applied to generate influenza hemagglutinin (HA) trimers without the need for trimerization domains. Additionally, we used TTT to generate well-folded chimeric Env and HA trimers that harbor protomers from three different strains. In summary, the TTT design is a useful platform for the design of HIV-1 Env and influenza HA immunogens for a multitude of vaccination strategies.
13 December 2025 in Nature Communications
The highly pathogenic avian influenza H5N1 virus clade 2.3.4.4b has been spreading globally since 2022, causing mortality and morbidity in domestic and wild birds, as well as in mammals, which underscores its potential to cause a pandemic. Here, we generate a panel of anti-hemagglutinin (HA) human monoclonal antibodies (mAbs) against the H5 protein of clade 2.3.4.4b. To develop human chimeric antibodies, H2L2 Harbor Mice®, which express human immunoglobulin germline genes, were immunized with H5 and N1 recombinant proteins from A/mallard/New York/22-008760-007- original/2022 H5N1 virus. Through hybridoma technology, sixteen fully human mAbs are generated, most of which show cross-reactivity against H5 proteins from different clade 2.3.4.4 virus variants. Fourteen out of the sixteen mAbs neutralize the virus in vitro. The mAbs with the strongest hemagglutination inhibition activity also demonstrate greater neutralizing capacity and show increased protective effects in vivo when administered prophylactically or therapeutically in a murine H5N1 challenge model. Using cryo-electron microscopy, we identify a cross-clonotype conserved motif that bound a hydrophobic groove on the head domain of H5 HA. Akin to mAbs against severe acute respiratory syndrome coronavirus 2 during the coronavirus 2019 pandemic, these mAbs could serve as treatments in case of a widespread H5N1 epidemic or pandemic.
1 May 2026 in Communications Medicine
Annual influenza vaccination is recommended for young children with limited understanding of how this may imprint influenza immunity. We conducted a pilot study to examine whether early life exposure to influenza through vaccination versus infection affects subsequent vaccination responses. Nineteen children aged 6-60 months were enrolled at two Australian hospitals during 2019-2021. Plasma was collected before and after vaccination for up to three successive years to measure antibody titres by hemagglutinination (HA) and neuraminidase (NA) inhibiting (HI, NI) assays and ELISA. Medical records and seropositivity (HI titre ≥40) at enrolment were used to classify seven children as having prior vaccination(s) and eight as having prior influenza A(H3N2) infection. Others had mixed, no, or unclear prior exposures. Post-vaccination antibody titres and seroconversion (HI fold-rise ≥4) were compared across the two main prior exposure groups. Here we show that post-vaccination HI and NI antibody titres and titre-rises against A(H3N2) are far higher among children classified as having had prior A(H3N2) infection compared to prior vaccination; 8/8 versus 3/7 seroconverted, respectively. A(H3N2) HA-stem binding antibody titres are modest but rise more after vaccination among children classified as having had prior A(H3N2) infection. A(H1N1)-reactive antibody responses are not significantly different between groups. These results suggest that for priming subsequent vaccine antibody responses against A(H3N2), infection may be superior to vaccination.